Osate 4 Mg/5 Ml Concentrate For Solution For Infusion
Out of date information, search anotherPACKAGE LEAFLET:
INFORMATION FOR THE PATIENT
Osate 4 mg/5 ml concentrate for solution for infusion
Zoledronic acid
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Osate is and what it is used for
2. What you need to know before you are given Osate
3. How to use Osate
4. Possible side effects
5. How to store Osate
6. Contents of the pack and other information
1. WHAT IS OSATE AND WHAT IS IT USED FOR
The active substance of Osate is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:
• To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).
• To reduce the amount of calcium
in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increa sed. This condition is known as tumour-induced hyper-calcaemia (TIH).
Osate will always be given to you by a doctor or a nurse as an infusion in a vein.
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN OSATE
Follow carefully all instructions given to you by your doctor.
Your doctor will carry out blood tests before you start treatment with Osate and will check your response to treatment at regular intervals.
You should not be given Osate:
• if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which Osate belongs), or any of the other ingredients of this medicine (listed in section 6.1)
• if you are breast-feeding. Warnings and precautions
Talk to your doctor or nurse before you are given Osate:
• if you have or have had a kidney problem
• if you have or have had pain, swelling or numbness of the
jaw, a feeling of heaviness in the jaw or loosening of a tooth
• if you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with Osate
• if you have any pain in your thigh, hip or groin. It is also important that you tell your doctor if you experience this after starting treatment with Osate (see section 4).
Children and adolescents Osate is not recommended for use in children and adolescents below the age of 18 years.
Patients aged 65 years and over Osate can be given to people aged 65 years and over. There is no
--------------
evidence to suggest that any extra precautions are needed.
Other medicines and Osate
Tell your doctor if you are taking or have recently taken any other medicines. It is especially important that you tell your doctor if you are also taking:
• Aminoglycosides (medicines used to treat severe infections), since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low
• Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys
• Other medicines that also contains zoledronic acid and is used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Osate are unknown
• Anti-angiogenic medicines (used to treat cancer), since the combination of these with Osate has been associated with reports of osteonecrosis of the jaw (ONJ).
Pregnancy, breast-feeding and fertility
You should not be given Osate if you are pregnant. Tell your doctor if you are or think that you may be pregnant.
You must not be given Osate if you are breast-feeding.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
There have been very rare cases of drowsiness and sleepiness with the use of Osate. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.
Important information about some of the ingredients in Osate
This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially sodium-free.
3. HOW OSATE IS GIVEN
• Osate must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein
• Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration
• Carefully follow all the other instructions given to you by your doctor, nurse or pharmacist.
How much Osate is given
• The usual single dose given is 4 mg
• If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.
How often Osate is given
• If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Osate every three to four weeks
• If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Osate.
How Osate is given
• Osate is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day. .../...
THE FOLLOWING INFORMATION IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY:
How to prepare and administer Osate
To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Osate concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. If a lower dose of Osate is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution. To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride or 5% w/v glucose solution.
Do not mix Osate concentrate with calcium-containing or other divalent cation-containing solutions such as lactated Ringer's solution.
Instructions for preparing reduced doses of Osate:
Withdraw the appropriate volume of the liquid concentrate, as follows:
• 4.4 ml for 3.5 mg dose
• 4.1 ml for 3.3 mg dose
• 3.8 ml for 3.0 mg dose
For single use only. Any unused solution should be discarded. Only clear solution free from particles and discolouration should be used. Aseptic techniques must be followed during the preparation of the infusion.
Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C;
however from a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and
If you are given more Osate than |
• Sudden coldness with fainting, |
you should |
limpness or collapse |
If you have received doses higher |
• Difficulty in breathing with |
than those recommended, you |
wheezing or coughing |
must be carefully monitored by |
• Urticaria. |
your doctor. This is because you |
Rare side effects |
may develop serum electrolyte |
(may affect up to 1 in 1.000 |
abnormalities (e.g. abnormal |
people): |
levels of calcium, phosphorus |
• Slow heartbeat |
and magnesium) and/or changes |
• Confusion |
in kidney function, including |
• Unusual fracture of the thigh |
severe kidney impairment. |
bone particularly in patients on |
If your level of calcium falls too |
long-term treatment for |
low, you may have to be given |
osteoporosis may occur rarely. |
supplemental calcium by |
Contact your doctor if you |
infusion; |
experience pain, weakness or |
If you have any further questions |
discomfort in your thigh, hip or |
on the use of this medicine, ask |
groin as this may be an early |
your doctor or nurse. |
indication of a possible fracture of the thigh bone |
4. POSSIBLE SIDE EFFECTS |
• Interstitial lung disease |
Like all medicines, this medicine |
(inflammation of the tissue |
can cause side effects, although |
around the air sacks of the |
not everybody gets them. The |
lungs) |
most common ones are usually |
Very rare side effects (may affect |
mild and will probably disappear |
up to 1 in 10.000 people): |
after a short time. |
• Fainting due to low blood |
Tell your doctor about any of the |
pressure |
following serious side effects |
• Severe bone, joint and/or |
straight away: |
muscle pain, occasionally |
Common side effects |
incapacitating |
(may affect up to 1 in 10 people): |
• Painful redness and/or swelling |
• Severe kidney impairment |
of the eye. |
(will normally be determined by |
If you get any side effects, talk to |
your doctor with certain |
your doctor or nurse. This |
specific blood tests); |
includes any possible side |
• Low level of calcium in the |
effects not listed in this leaflet. |
blood. |
You can also report side effects |
Uncommon side effects |
directly via Yellow Card Scheme, |
(may affect up to 1 in 100 people): |
Tel: Freephone 0808 100 3352 |
• Pain in the mouth, teeth and/or |
Website: |
jaw, swelling or sores inside the | |
mouth, numbness or a feeling of |
By reporting side effects you can |
heaviness in the jaw, or |
help provide more information on |
loosening of a tooth. These could be signs of bone damage |
the safety of this medicine. |
in the jaw (osteonecrosis). Tell |
5. HOW TO STORE OSATE |
your doctor and dentist |
Your doctor, nurse or pharmacist |
immediately if you experience |
knows how to store Osate |
such symptoms |
properly. |
• Irregular heart rhythm (atrial |
Keep this medicine out of the |
fibrillation) has been seen in |
sight and reach of children. |
patients receiving zoledronic |
Do not throw away any medicines |
acid for postmenopausal |
via wastewater. Ask you |
osteoporosis. It is currently |
pharmacist how to throw away |
unclear whether zoledronic |
medicines you no longer use. |
acid causes this irregular heart |
These measures will help protect |
rhythm but you should report it |
the environment. |
to your doctor if you experience |
Do not use this medicine after the |
such symptoms after you have |
expiry date which is stated on the |
received zoledronic acid |
carton and vial label after EXP. |
• Severe allergic reaction: |
The expiry date refers to the last |
shortness of breath, swelling |
day of that month. |
mainly of the face and throat. |
This medicine does not require |
Tell your doctor about any of the |
any special storage conditions |
following side effects as soon as |
until the vial has been opened and |
possible: Very common side effects |
the concentrate is diluted. |
(may affect more than 1 in 10 |
6. CONTENTS OF THE PACK AND |
people): |
OTHER INFORMATION |
• Low level of phosphate in the |
What Osate contains |
blood. |
• The active substance of Osate |
Common side effects |
is zoledronic acid. One vial |
(may affect up to 1 in 10 people): |
contains 4 mg zoledronic acid, |
• Headache and a flu-like |
corresponding to 4.264 mg |
syndrome consisting of fever, |
zoledronic acid monohydrate |
fatigue, weakness, drowsiness, |
(as monohydrate), |
chills and bone, joint and/or |
corresponding to 4.264 mg |
muscle ache. In most cases no |
zoledronic acid monohydrate. |
specific treatment is required |
• The other ingredients are: |
and the symptoms disappear |
mannitol, sodium citrate, water |
after a short time (couple of |
for injections. |
hours or days) |
What Osate looks like and |
• Gastrointestinal reactions such |
contents of the pack |
as nausea and vomiting as well |
Osa te is supplied as a liquid |
as loss of appetite |
concentrate in a vial. One vial |
• Conjunctivitis |
contains 4 mg of zoledronic acid. |
• Low level of red blood cells |
Each pack contains the vial with |
(anaemia). |
concentrate. Osate is supplied as |
Uncommon side effects |
packs containing 1, 4 or 10 vials. |
(may affect up to 1 in 100 people): |
Not all pack sizes may be |
• Hypersensitivity reactions |
marketed. |
• Low blood pressure |
Marketing Authorisation Holder |
• Chest pain |
and Manufacturer |
• Skin reactions (redness and |
Marketing Authorisation Holder |
swelling) at the infusion site, |
STRAGEN UK Ltd |
rash, itching |
Castle Court, 41 London Road |
• High blood pressure, shortness |
Reigate, Surrey RH2 9RJ |
of breath, dizziness, sleep |
Phone: +44 (0)870 351 87 44 |
disturbances, tingling or |
Email: info@stragenuk.com |
numbness of the hands or feet, |
Manufacturer |
diarrhoea |
Lisa Pharma |
• Low counts of white blood cells |
Via Licinio 11, 22036 ERBA (Como) |
and blood platelets • Low level of magnesium and |
Italy |
potassium in the blood. Your |
This leaflet was last revised in |
doctor will monitor this and take any necessary measures • Sleepiness |
04/2013 |
• Tearing of the eye, eye |
■ 1 1 1 1 1 \i $ 1 1 1 1 1 ■ |
sensitivity to light | |
conditions prior to use are the |
Since no data are available on the |
responsibility of the user and |
compatibility of Osate with other |
would normally not be longer than |
intravenously administered substan- |
24 hours at 2°C - 8°C. |
ces, Osate must not be mixed with |
The refrigerated solution should |
other medications/substances and |
then be equilibrated to room |
should always be given through a |
temperature prior to administration. |
separate infusion line. |
The solution containing zoledronic |
How to store Osate |
acid is given as a single 15-minute |
• Keep Osate out of the sight and |
intravenous infusion in a separate |
reach of children |
infusion line. The hydration status |
• Do not use Osate after the |
of patients must be assessed |
expiry date stated on the pack |
prior to and following adminis- |
• The unopened vial does not |
tration of Osate to ensure that |
require any specific storage |
they are adequately hydrated. |
conditions |
Studies with several types of |
• The diluted Osate infusion |
infusion lines made from |
solution should be used |
polyvinylchloride, polyethylene |
immediately in order to avoid |
and polypropylene showed no incompatibility with Osate. |
microbial contamination. |